Clinical trials: Depression / Major Depressive Disorder
Bipolar Disorder, Bipolar Depression
PET and MRI Brain Imaging of Bipolar Disorder
The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2.
- Conditions
- Bipolar Disorder, Bipolar Depression, Unipolar Depression
- Trial name
- NCT01880957
- Testing
- Lithium, Lamotrigine
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Major Depressive Disorder
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD).
- Trial name
- tVNS_MDD_Sex (NCT04448327)
- Testing
- active tVNS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Improving Therapeutic Learning in Depression: Proof of Concept
Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments.
- Trial name
- NCT02376257
- Testing
- 250 mg DCS, 100 mg Modafinil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston University Charles River Campus
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00798707
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR)
- Where
- 78 sites in United States, Japan
- Volunteers
- 709 people
- Sponsor
- Pfizer
Bipolar II Disorder, Major Depressive Episode
Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression
The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
- Trial name
- NCT00237666
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- The Medical Research Network
Anxious Major Depressive Disorder
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.
- Trial name
- NCT00759395
- Testing
- AZD2327
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild - Major Depression
Internet-delivered Psychotherapy for Depression
Project aim: To compare the effectiveness and acceptability of a conventional and a religious internet-supported cognitive behavior therapy (iCBT) for depression in Romania.
- Trial name
- PsiTOD (NCT02091856)
- Testing
- Cognitive Behavioral Therapy (CBT)
- Where
- Romania
- Volunteers
- 79 people
- Sponsor
- West University of Timisoara
Major Depression
Spirituality Teaching Program for Depressed Adults
Major depression is a widely spread health problem in Canada. Recent research suggests a potential role for religion/spirituality in the prevention of and recovery from depression in adults.
- Trial name
- NCT00322777
- Testing
- Spirituality Teaching Program
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Canadian Institute of Natural and Integrative Medicine
Major Depressive Disorder
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved…
- Trial name
- STEP-D222 (NCT01052077)
- Testing
- OPC-34712, ADT
- Where
- 43 sites in United States
- Volunteers
- 773 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
- Trial name
- NCT00422162
- Testing
- Duloxetine hydrochloride
- Where
- 35 sites in France, Italy and 2 more
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Depression, Major Depressive Disorder
Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Major depressive disorder (MDD) is a global medical problem with significant shortcomings in current therapy. Chief among these is the delay between initiation of pharmacologic therapy and clinical improvement in symptoms.
- Trial name
- NCT02139540
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Major Depression, Treatment
fMRI Study of Treatment Changes in Major Depression
The overall purposes of this research are to determine if Cognitive Behavioral Therapy (CBT) has the same healing effect on the brain for people with depression as traditional antidepressants do, and in comparison to healthy…
- Trial name
- NCT01027559
- Testing
- Sertraline, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Cognitive Behavior Therapy
Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework
The primary goal of the pilot is to test the feasibility and utility of using a text-messaging system to engage adolescents in improved homework adherence during cognitive-behavioral therapy (CBT) for major depressive disorder.
- Conditions
- Major Depressive Disorder, Cognitive Behavior Therapy, Text Messaging
- Trial name
- NCT00919932
- Testing
- Paper and pen homework, Text message system homework.
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depression
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.
- Trial name
- NCT03000530
- Testing
- SAGE-217
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Biogen
Major Depression
Brain Imaging of Quetiapine Response in Anxious Depression
The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients.
- Trial name
- NCT00982345
- Testing
- quetiapine (Seroquel XR)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mental Disorders, Severe, Schizophrenia and Related Disorders
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
Insufficient community-based support after inpatient discharge for persons with serious mental illnesses (SMI) may lead to re-hospitalization, excessive criminal justice involvement, homelessness, and an inability to embrace…
- Conditions
- Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
- Trial name
- ODR (NCT04612777)
- Testing
- Opening Doors to Recovery, Case Management, Intensive Case Management
- Volunteers
- 240 people
- Sponsor
- New York State Psychiatric Institute